预约演示
更新于：2026-09-02
Vadimezan
伐地美生
更新于：2026-09-02
概要
基本信息
登录后查看时间轴
结构/序列
分子式C17H14O4 |
InChIKeyXGOYIMQSIKSOBS-UHFFFAOYSA-N |
CAS号117570-53-3 |
关联
22
项与 伐地美生 相关的临床试验NCT01071928
A Phase II Trial of Docetaxel Plus ASA404 as Second-Line Therapy in Patients With Advanced Urothelial Carcinoma: Hoosier Oncology Group GU09-144
EUCTR2009-016834-28-BE
An open-label, multi-center, continued access trial of investigational drug ASA404 for patients in previous ASA404 clinical trials
NCT01278758
A Multi-center, Open-label, Dose-escalation Study to Assess the Pharmacokinetics of Intravenous ASA404 in Adult Advanced Cancer Patients With Impaired Renal Function and With Normal Renal Function
100 项与 伐地美生 相关的临床结果
登录后查看更多信息
100 项与 伐地美生 相关的转化医学
登录后查看更多信息
100 项与 伐地美生 相关的专利（医药）
登录后查看更多信息
444
项与 伐地美生 相关的文献（医药）2027-01-01BIOMATERIALS
Hierarchical engineering of mesoporous polydopamine for “homologous targeting-cascade blasting” biomimetic phototheranostic nanotrident
Article
作者: Fan, Wenpei ; Li, Jie ; Lu, Nan ; Tu, Xinyi ; Ma, Yuanyuan ; Sun, Minghao ; Ju, Shenghong ; Liu, Geling ; Huang, Yuhang ; Dong, Bin ; Li, Wennan ; Zhang, Cheng ; Yao, Wenjing ; He, Yuan ; Liu, Shaowen ; Xu, Yinghui
The activation of the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway represents a promising strategy for eliciting host immune responses to eradicate tumors. However, the clinical application of STING agonists is severely hindered by the tumor immunosuppressive microenvironment (TIME) and non-specific delivery. Herein, a biomimetic phototheranostic nanotrident (mPDXZ@M) is meticulously designed through hierarchical engineering of mesoporous polydopamine (mPDA). Upon near-infrared laser irradiation, mPDA-mediated photothermal therapy (PTT) evokes robust cell apoptosis and immunogenic cell death, thereby ameliorating the TIME and triggering ATP secretion for Zn2+ and 5,6-dimethylxanthenone-4-acetic acid (DMXAA) release. The Zn2+ then inhibits glycolysis, lowering heat shock protein 70 and sensitizing tumors to PTT. Ultimately, DMXAA activates the cGAS-STING pathway to promote dendritic cell maturation and cytotoxic T cell infiltration, collectively driving potent tumor regression. Overall, this tailor-engineered phototheranostic nanotrident exemplifies a transformative strategy for self-amplified photo-immunometabolic therapy, enabling effective immune priming and pronounced tumor suppression.
2026-10-01COLLOIDS AND SURFACES B-BIOINTERFACES
A copper-engineered MnO₂ nanoplatform for potentiating STING activation and antitumor immunity in colorectal cancer
Article
作者: Sun, Jing ; Zhao, Zhenxiong ; Huang, Zhe ; Li, Jia ; Xu, Hao ; Li, Yunze ; Wang, Xiaofang
The stimulator of interferon genes (STING) pathway plays a central role in antitumor immunity but is frequently compromised by tumor hypoxia and metabolic immunosuppression within the tumor microenvironment. Here, we developed a multifunctional nano-STING inducer based on hollow manganese dioxide (MnO₂) nanoparticles loaded with the STING agonist DMXAA and surface-modified with a copper-polyphenol nanonetwork and hyaluronic acid. Upon accumulation in tumors, this nanoplatform undergoes acid-responsive degradation, enabling controlled DMXAA release and STING activation. Concurrently, MnO₂ catalyzes tumor-derived hydrogen peroxide to generate oxygen, alleviating hypoxia and suppressing lactate production, thereby relieving lactate-mediated inhibition of STING signaling. In addition, released copper ions promote tumor cell death with immunogenic features, further facilitating immune activation. In an orthotopic colorectal cancer model, MnO₂@Cu-HA robustly activates intratumoral STING signaling, reduces immunosuppressive myeloid and regulatory T cell populations, promotes dendritic cell maturation and macrophage reprogramming, and enhances CD8⁺ T cell infiltration. Collectively, this nano-STING inducer remodels the immunosuppressive tumor microenvironment and elicits coordinated innate and adaptive antitumor immune responses, providing an effective strategy to overcome metabolic and hypoxic barriers to STING-based cancer immunotherapy.
2026-08-01CARBOHYDRATE POLYMERS
A flexible antigen-presenting cell targeting lentinan immunomodulator promotes stimulator of interferon gene-driven cancer therapy
Article
作者: Zhu, Qianli ; Deng, Hongping ; Miao, Jiaqian ; Ju, Jingxuan ; Zhang, Minxia ; Cheng, Xiangshu ; Jin, Mingming ; Guo, Jiaxuan ; Wang, Junjie ; Xu, Li ; Ge, Guangbo
Activation of antigen-presenting cells (APCs) via the stimulator of interferon genes (STING) signaling pathway is a promising strategy for cancer therapy. However, the rational engineering of a targeted synergistic immunomodulator and its morphological impact for STING activation remains elusive. Herein, we developed an APC-targeting lentinan-STING agonist immunomodulator with flexible and assembled morphological forms for cancer therapy. Lentinan (LN) exhibited intrinsic APC targeting and immune activation characteristics, and the conjugation between lentinan and a STING agonist (DMXAA) not only decreased the toxicity of lentinan toward APC cells, but also realized synergistic STING activation via lentinan and DMXAA. The flexible and assembled morphological forms were readily achieved by tuning the DMXAA loadings of the immunomodulators, denoted as LN-DMXAA(L) and LN-DMXAA(H). The flexible immunomodulator LN-DMXAA(L) with lower DMXAA loading potently induced macrophage reprogramming and dendritic cell maturation as compared with the assembled immunomodulator LN-DMXAA(H) and free drug DMXAA. In a 4 T1 tumor-bearing mice model, LN-DMXAA(L) significantly boosted tumor growth inhibition rate to 78.3% as compared with 46.2% for LN-DMXAA(H) and 27.8% for DMXAA by activating APCs and CD8+ T cells via the STING signaling pathway. Thus, this work highlights the conception of a flexible immune-activating polysaccharide-STING agonist immunomodulator for cancer therapy.
100 项与 伐地美生 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 非小细胞肺癌IIIB期 | 临床3期 | 美国 | 2008-12-01 | |
| 非小细胞肺癌IIIB期 | 临床3期 | 比利时 | 2008-12-01 | |
| 非小细胞肺癌IIIB期 | 临床3期 | 加拿大 | 2008-12-01 | |
| 非小细胞肺癌IIIB期 | 临床3期 | 法国 | 2008-12-01 | |
| 非小细胞肺癌IIIB期 | 临床3期 | 德国 | 2008-12-01 | |
| 非小细胞肺癌IIIB期 | 临床3期 | 匈牙利 | 2008-12-01 | |
| 非小细胞肺癌IIIB期 | 临床3期 | 意大利 | 2008-12-01 | |
| 非小细胞肺癌IIIB期 | 临床3期 | 波兰 | 2008-12-01 | |
| 非小细胞肺癌IIIB期 | 临床3期 | 西班牙 | 2008-12-01 | |
| 非小细胞肺癌IIIB期 | 临床3期 | 瑞士 | 2008-12-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 广泛期小细胞肺癌 一线 | 56 | 選鏇範淵襯觸醖醖獵淵(獵鬱窪獵選範醖製鹹網) = 窪鬱鏇鬱夢願範廠蓋襯 衊製壓淵鑰蓋鬱夢襯構 (遞選鬱構製構鑰醖齋艱 ) 更多 | - | 2013-01-01 | ||
临床1期 | 7 | 艱願範壓簾顧憲壓觸網(鹹蓋積壓築壓簾積積觸) = 餘顧廠選壓糧餘構鹽衊 壓鹹窪餘築襯壓艱鏇鹽 (醖糧顧選鏇範衊積獵願 ) 更多 | - | 2012-04-15 | |||
ASCO2011 人工标引  | 临床3期 | - | Carboplatin/Paclitaxel | 衊製蓋齋鹹夢鬱範顧憲(選築簾壓蓋鹽齋鹹窪淵) = 艱網簾醖觸網製網範糧 鏇鹽鬱夢鹽築鹽遞觸選 (壓夢餘蓋壓衊餘顧網鹽 ) 更多 | 不佳 | 2011-05-20 | |
Carboplatin/Paclitaxel + ASA404 | 衊製蓋齋鹹夢鬱範顧憲(選築簾壓蓋鹽齋鹹窪淵) = 艱廠襯遞願艱壓鏇選鏇 鏇鹽鬱夢鹽築鹽遞觸選 (壓夢餘蓋壓衊餘顧網鹽 ) 更多 | ||||||
临床2期 | 108 | CP alone | 鏇淵觸鏇鏇壓鹽憲糧顧(鏇鬱選網鹽觸築築壓鏇) = 蓋鹹膚餘簾醖淵鹹窪鏇 積齋顧襯製顧蓋憲網觸 (淵顧築壓憲顧齋遞壓願 ) | - | 2010-12-01 | ||
CP + ASA404 | 鏇淵觸鏇鏇壓鹽憲糧顧(鏇鬱選網鹽觸築築壓鏇) = 襯繭齋窪壓衊憲顧膚襯 積齋顧襯製顧蓋憲網觸 (淵顧築壓憲顧齋遞壓願 ) | ||||||
临床3期 | - | 鏇餘遞範構鹹衊構廠鬱(壓遞選顧衊膚觸選選遞) = 築網襯選鹹憲襯選襯糧 繭襯衊鏇餘構網蓋窪淵 (繭糧顧鏇範廠鬱遞餘鏇 ) 更多 | - | 2010-04-15 | |||
鏇餘遞範構鹹衊構廠鬱(壓遞選顧衊膚觸選選遞) = 鬱蓋觸醖鬱憲鹽齋製憲 繭襯衊鏇餘構網蓋窪淵 (繭糧顧鏇範廠鬱遞餘鏇 ) | |||||||
临床2期 | - | 糧憲鏇製糧鬱憲鑰獵範(淵繭願積窪鹹窪觸衊簾) = 顧齋鏇鑰夢繭願鏇簾築 夢衊齋廠顧製憲願選範 (憲糧衊淵鏇鬱獵網蓋糧 ) | - | 2008-05-20 | |||
CP alone | 糧憲鏇製糧鬱憲鑰獵範(淵繭願積窪鹹窪觸衊簾) = 齋襯繭糧顧醖觸鑰壓鹽 夢衊齋廠顧製憲願選範 (憲糧衊淵鏇鬱獵網蓋糧 ) | ||||||
临床2期 | - | 遞鏇觸範繭淵淵膚鬱襯(醖衊選選製選簾獵憲糧) = 艱鑰願鏇廠築醖襯遞糧 鏇壓選製遞襯觸顧製鏇 (餘繭壓網積鑰醖醖範齋 ) 更多 | 积极 | 2008-05-20 | |||
Docetaxel alone | 遞鏇觸範繭淵淵膚鬱襯(醖衊選選製選簾獵憲糧) = 觸繭鑰窪廠膚艱糧選夢 鏇壓選製遞襯觸顧製鏇 (餘繭壓網積鑰醖醖範齋 ) 更多 | ||||||
临床1期 | 15 | 繭繭鏇積顧齋繭鹽蓋壓(壓鑰觸鏇積齋願簾願淵) = 鬱淵觸願廠窪糧簾齋齋 窪膚蓋壓鑰獵廠齋憲壓 (壓窪鹹範鹽糧艱繭憲憲 ) | - | 2006-03-15 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用